FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite ...
--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. a pioneer in molecular profiling for cancer, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for ...
With a single tissue biopsy and comprehensive genomic profiling (CGP), people diagnosed with cancer have access to more information about their disease than ever before. These insights are rapidly ...
CAMBRIDGE, Mass. & AUSTIN, Texas--(BUSINESS WIRE)-- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, ...
The FDA approved this liquid biopsy to check blood for prostate-tumor DNA that indicates the presence of genetic mutations or rearrangements. The test was also recently approved for use in patients ...
The FDA approved the FoundationOne CDx test to help identify certain neurotrophic receptor tyrosine kinase gene fusions in patients with solid tumors eligible for treatment with larotrectinib, ...
The Food and Drug Administration (FDA) approved FoundationOne Liquid CDx, a comprehensive multi-tumor liquid biopsy test, for all solid tumors with multiple companion diagnostic indications, according ...
Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results